Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Merck & Co. is providing Harvard Medical School professor Arlene Sharpe with an undisclosed amount of research funding for 4 years. Sharpe, who is chair of the Department of Immunology, helped discover the function of PD-1, a protein that is targeted by checkpoint inhibitor cancer therapies, including Merck’s Keytruda. Merck hopes to discover new immunotherapy drug targets. Separately, the German messenger-RNA-therapy company CureVac signed an agreement with Yale University pulmonologist Geoffrey Chupp to conduct preclinical research on mRNA therapies for lung diseases.
This article has been sent to the following recipient: